Alpha Teknova, Inc. (TKNO): Business Model Canvas [11-2024 Updated]
- ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
- ✓ Professional Design: Trusted, Industry-Standard Templates
- ✓ Pre-Built For Quick And Efficient Use
- ✓ No Expertise Is Needed; Easy To Follow
Alpha Teknova, Inc. (TKNO) Bundle
In the rapidly evolving landscape of biotechnology, understanding the business model of a company like Alpha Teknova, Inc. (TKNO) is crucial for investors and industry enthusiasts alike. This post delves into the Business Model Canvas of Alpha Teknova, highlighting key elements such as partnerships, activities, and value propositions. Discover how this innovative company navigates the complex world of diagnostics and therapeutics, ensuring high-quality solutions and compliance in a competitive market.
Alpha Teknova, Inc. (TKNO) - Business Model: Key Partnerships
Collaboration with suppliers for raw materials
Alpha Teknova relies on a limited number of suppliers for certain raw materials, with no long-term supply arrangements, ordering on a purchase order basis. As of September 30, 2024, a significant supplier accounted for 37% of the company's inventory purchases. The total inventories, net, were valued at $7.674 million, showing a decrease from $11.594 million as of December 31, 2023.
Partnerships with distributors for product delivery
The company generates a substantial portion of its revenue from distributor relationships. For the three months ended September 30, 2024, distributor customer A accounted for 19% of revenues, while distributor customer B contributed less than 10%. The overall revenue for the same period was $9.576 million, reflecting a year-over-year increase of $1.407 million from $8.169 million in 2023.
Engagement with research institutions for innovation
Alpha Teknova collaborates with more than 2,500 active customers, including leading pharmaceutical companies and academic institutions, to drive innovation in product development. This engagement supports their product categories, such as Lab Essentials and Clinical Solutions, which are crucial for the development of therapies and diagnostics.
Relationships with regulatory bodies for compliance
The company is ISO 13485:2016 certified, which is essential for compliance in manufacturing products for diagnostic and therapeutic applications. This certification enables Teknova to meet stringent quality requirements and ensures that their products are suitable for commercialization. Compliance with regulatory standards is critical for maintaining partnerships and customer trust in a highly regulated industry.
Alpha Teknova, Inc. (TKNO) - Business Model: Key Activities
Manufacturing of diagnostic and therapeutic products
Alpha Teknova, Inc. manufactures a variety of diagnostic and therapeutic products at its facility in Hollister, California. The company has ISO 13485:2016 certification, allowing it to produce products that meet stringent quality requirements for both research and commercial applications. In the three months ended September 30, 2024, Teknova generated revenue of $9.6 million, reflecting an increase from $8.2 million in the same period of 2023.
Quality control and regulatory compliance processes
Quality control is a critical component of Teknova's manufacturing process. The company adheres to strict regulatory compliance standards to ensure product safety and efficacy. As of September 30, 2024, the cost of sales was $9.5 million, which indicates the expenses associated with maintaining quality throughout production.
Research and development for product innovation
Research and development (R&D) is vital for Teknova to innovate and expand its product offerings. R&D expenses were $2.2 million for the nine months ended September 30, 2024, down from $4.3 million in the same period in 2023, reflecting a 49.1% decrease. This reduction was primarily driven by decreased headcount and supplies expense.
Sales and marketing to expand market reach
Sales and marketing efforts are essential for Teknova to enhance its market presence. Sales and marketing expenses were $4.8 million for the nine months ended September 30, 2024, compared to $6.9 million in the same period of 2023, representing a 31.3% decrease. This decline was attributed to reduced headcount and a strategic shift in marketing initiatives.
| Activity | Details | Financial Data (Q3 2024) |
|---|---|---|
| Manufacturing | Production of diagnostic and therapeutic products | $9.6 million revenue |
| Quality Control | ISO 13485:2016 certified processes | $9.5 million cost of sales |
| Research & Development | Focus on product innovation | $2.2 million R&D expenses |
| Sales & Marketing | Efforts to expand market reach | $4.8 million sales & marketing expenses |
Alpha Teknova, Inc. (TKNO) - Business Model: Key Resources
ISO 13485:2016 Certification for Quality Assurance
Alpha Teknova, Inc. is ISO 13485:2016 certified, which enables the company to manufacture products for diagnostic and therapeutic applications. This certification ensures compliance with stringent quality requirements necessary for the development of medical devices and related services, enhancing customer confidence and marketability of their products.
Manufacturing Facilities in Hollister, California
Teknova operates its manufacturing facilities in Hollister, California. As of September 30, 2024, the company reported property, plant, and equipment (net) valued at approximately $46.7 million. The facilities are equipped to produce a range of critical reagents and have a capacity to support both small-scale and large-scale production needs.
Inventory of Raw Materials and Finished Goods
As of September 30, 2024, Teknova's inventory consisted of the following (in thousands):
| Inventory Type | Value (USD) |
|---|---|
| Finished Goods, Net | $5,235 |
| Work in Process | $134 |
| Raw Materials, Net | $2,305 |
| Total Inventories, Net | $7,674 |
This inventory structure supports Teknova's operations by ensuring that sufficient raw materials and finished products are available to meet customer demand while optimizing production efficiency.
Skilled Personnel for Production and R&D
Teknova employs skilled personnel dedicated to production and research & development (R&D). The company emphasizes the importance of human resources in maintaining operational excellence and innovation. As of September 30, 2024, the company reported total operating expenses related to research and development amounting to $2.2 million for the nine months ended. This investment reflects the company's commitment to advancing its product offerings and improving manufacturing processes.
Alpha Teknova, Inc. (TKNO) - Business Model: Value Propositions
High-quality products for diagnostic applications
Alpha Teknova, Inc. specializes in the production of high-quality products specifically designed for diagnostic applications. The company has achieved ISO 13485:2016 certification, enabling it to manufacture products that meet stringent quality requirements for both diagnostic and therapeutic applications. In the third quarter of 2024, Teknova reported a total revenue of $9.6 million, an increase of 17.2% compared to $8.2 million in the same quarter of the previous year.
Customizable solutions to meet client needs
The company offers customizable solutions tailored to the specific needs of its clients. This flexibility allows Teknova to support its customers throughout the product development lifecycle, from initial research to commercialization. The revenue generated from Clinical Solutions rose to $2.0 million for the three months ended September 30, 2024, representing a 229% increase compared to the same period in 2023.
Support throughout the product development lifecycle
Alpha Teknova provides comprehensive support throughout the product development lifecycle, which includes assistance in scaling production and ensuring compliance with regulatory standards. For the nine months ended September 30, 2024, the company reported a gross profit of $5.1 million, although this represented a decrease of 43.1% from the same period in 2023 due to non-recurring charges related to inventory. This support is critical for clients as they transition from research phases to larger-scale manufacturing.
Commitment to regulatory compliance and safety standards
Alpha Teknova's commitment to regulatory compliance is reflected in its adherence to safety standards and certifications such as ISO 13485:2016. This ensures that their products not only meet quality standards but also regulatory requirements essential for diagnostic applications. As of September 30, 2024, the company reported an accumulated deficit of $112.8 million, highlighting the financial challenges faced during its growth phase.
| Financial Metric | Q3 2024 | Q3 2023 | % Change |
|---|---|---|---|
| Total Revenue | $9.6 million | $8.2 million | 17.2% |
| Gross Profit | $90,000 | $1.472 million | (93.9%) |
| Clinical Solutions Revenue | $2.0 million | $0.6 million | 229% |
| Operating Loss | $7.4 million | $8.8 million | 16.9% |
| Accumulated Deficit | $112.8 million | $91.8 million | 22.0% |
Alpha Teknova, Inc. (TKNO) - Business Model: Customer Relationships
Direct engagement through dedicated sales teams
Alpha Teknova, Inc. employs dedicated sales teams to foster direct engagement with customers. For the nine months ended September 30, 2024, the company reported total revenue of $28.5 million, reflecting a slight decrease of 1.2% from $28.8 million in the same period in 2023. This revenue is supported by a diversified customer base of more than 2,500 active customers, including pharmaceutical and biotechnology companies, contract development organizations, and academic institutions.
Technical support for product applications
Technical support is a cornerstone of Alpha Teknova’s customer service strategy. The company provides comprehensive assistance for product applications, which is crucial given its focus on critical reagents used in diagnostics and therapeutics. For instance, Clinical Solutions revenue was $5.2 million for the nine months ended September 30, 2024, which decreased by 10.4% compared to the same period in 2023, primarily due to lower average revenue per customer despite an increase in the number of customers.
Feedback loops for continuous improvement
Alpha Teknova incorporates feedback loops as part of its customer relationship management. This approach allows the company to adjust its offerings based on customer input, thereby enhancing product quality and customer satisfaction. The company's gross profit margin decreased significantly, from 31.1% in 2023 to 17.9% in 2024, indicating a need for continuous improvement strategies to address cost challenges and optimize customer service.
Building long-term partnerships with clients
Building long-term partnerships is integral to Alpha Teknova’s business model. The company focuses on creating lasting relationships with its clients by offering tailored solutions and maintaining high standards of quality, as evidenced by its ISO 13485:2016 certification. This certification enhances the company's credibility in delivering high-quality products that meet stringent regulatory requirements. The company’s customer relationships are also supported by its diverse revenue streams, with Lab Essentials revenue remaining stable at $22.1 million for the nine months ended September 30, 2024.
| Customer Engagement Strategy | Key Metrics |
|---|---|
| Direct Engagement with Dedicated Sales Teams | Total Revenue: $28.5 million (2024); $28.8 million (2023) |
| Technical Support for Product Applications | Clinical Solutions Revenue: $5.2 million (2024); $5.9 million (2023) |
| Feedback Loops for Continuous Improvement | Gross Profit Margin: 17.9% (2024); 31.1% (2023) |
| Building Long-term Partnerships | Lab Essentials Revenue: $22.1 million (2024); $22.1 million (2023) |
Alpha Teknova, Inc. (TKNO) - Business Model: Channels
Direct sales to customers and distributors
Alpha Teknova, Inc. generates a significant portion of its revenue through direct sales to customers, including pharmaceutical and biotechnology companies, as well as through distributor relationships. For the three months ended September 30, 2024, the company reported total revenue of $9.6 million, reflecting a year-over-year increase of approximately 17% from $8.2 million during the same period in 2023. In the nine months ended September 30, 2024, revenue totaled $28.5 million, slightly down from $28.8 million in 2023.
Online platforms for product information
Alpha Teknova utilizes its website and online platforms to provide detailed product information, facilitating customer engagement and education. This strategy enhances visibility and access to their offerings, which include critical reagents for life sciences applications. The company has over 2,500 active customers, spanning various segments of the life sciences market.
Participation in industry trade shows and conferences
Participation in industry trade shows and conferences is a crucial channel for Alpha Teknova. These events allow the company to showcase its products, engage with potential customers, and network with industry professionals. The company allocates a portion of its sales and marketing expenses to these events, which amounted to approximately $1.64 million for the three months ended September 30, 2024.
Networking with healthcare professionals and organizations
Networking efforts with healthcare professionals and organizations play a vital role in Alpha Teknova's marketing strategy. By establishing connections with key industry players, the company can better understand market needs and enhance its product offerings. The company's sales and marketing expenses for the nine months ended September 30, 2024, were approximately $4.76 million, reflecting ongoing investment in building these relationships.
| Channel | Details | Financial Impact |
|---|---|---|
| Direct Sales | Sales to pharmaceutical and biotechnology companies, distributors | $9.6 million revenue (Q3 2024) |
| Online Platforms | Website providing product information and customer engagement | Over 2,500 active customers |
| Trade Shows | Participation in industry events for visibility and networking | $1.64 million in sales and marketing expenses (Q3 2024) |
| Networking | Connections with healthcare professionals and organizations | $4.76 million in sales and marketing expenses (9M 2024) |
Alpha Teknova, Inc. (TKNO) - Business Model: Customer Segments
Healthcare providers and laboratories
Alpha Teknova serves a variety of healthcare providers and laboratories, providing critical materials necessary for diagnostics and therapeutic applications. Revenue from U.S. sales to healthcare providers was approximately $27.2 million for the nine months ended September 30, 2024, representing 95.3% of total revenue, which is consistent with the previous year.
Research institutions in biotechnology and pharmaceuticals
Research institutions are pivotal to Teknova’s customer base, particularly in the biotechnology and pharmaceutical sectors. The demand for lab essentials and clinical solutions has driven revenue growth, with Lab Essentials revenue holding steady at $22.1 million for the nine months ending September 30, 2024.
Companies in cell and gene therapy sectors
Alpha Teknova is increasingly focusing on customers in the cell and gene therapy sectors, where the company has seen a significant rise in Clinical Solutions revenue. For the three months ended September 30, 2024, Clinical Solutions revenue surged to $2.0 million, up 229% from $0.6 million in the same period in 2023, reflecting a growing customer base in this innovative field.
International clients, though primarily U.S.-based
While primarily serving U.S.-based clients, Alpha Teknova has started to expand its international footprint. International sales accounted for $1.3 million, or 4.7% of total revenue, for the nine months ended September 30, 2024, showing an increase from $1.2 million in the previous year.
| Customer Segment | Revenue (9 months ended Sept 30, 2024) | Percentage of Total Revenue | Growth from 2023 |
|---|---|---|---|
| Healthcare providers and laboratories | $27.2 million | 95.3% | -1.7% |
| Research institutions in biotechnology and pharmaceuticals | $22.1 million | 77.7% | 0.0% |
| Companies in cell and gene therapy sectors | $2.0 million | 7.0% | 229.0% |
| International clients | $1.3 million | 4.7% | 11.4% |
Alpha Teknova, Inc. (TKNO) - Business Model: Cost Structure
Manufacturing and operational costs
The manufacturing and operational costs for Alpha Teknova, Inc. include expenses associated with the production of their products and maintaining operational efficiency. For the three months ended September 30, 2024, the cost of sales was $9.5 million, an increase of 41.6% compared to $6.7 million for the same period in 2023. For the nine months ended September 30, 2024, the total cost of sales was $23.4 million, up from $19.9 million in 2023, reflecting a 17.7% increase.
| Period | Cost of Sales ($ millions) | Percentage Change (%) |
|---|---|---|
| Q3 2024 | 9.5 | 41.6 |
| YTD Q3 2024 | 23.4 | 17.7 |
Research and development expenses
Research and development (R&D) expenses are critical for product innovation at Alpha Teknova. In Q3 2024, R&D expenses amounted to $0.6 million, a decrease of 55.1% from $1.4 million in Q3 2023. For the nine months ended September 30, 2024, R&D expenses totaled $2.2 million, down from $4.3 million in the previous year, marking a 49.1% reduction.
| Period | R&D Expenses ($ millions) | Percentage Change (%) |
|---|---|---|
| Q3 2024 | 0.6 | -55.1 |
| YTD Q3 2024 | 2.2 | -49.1 |
Marketing and sales expenditures
Marketing and sales expenditures are essential for customer acquisition and retention. In Q3 2024, these expenses were $1.6 million, a decrease of 32.0% from $2.4 million in Q3 2023. For the nine months ended September 30, 2024, marketing expenses totaled $4.8 million, down from $6.9 million in 2023, reflecting a 31.3% decline.
| Period | Sales & Marketing Expenses ($ millions) | Percentage Change (%) |
|---|---|---|
| Q3 2024 | 1.6 | -32.0 |
| YTD Q3 2024 | 4.8 | -31.3 |
Compliance and regulatory costs
Compliance and regulatory costs are integral to maintaining quality standards and certifications. General and administrative expenses, which include compliance costs, were $5.0 million in Q3 2024, down from $6.1 million in Q3 2023, representing a decrease of 19.1%. For the nine months ended September 30, 2024, general and administrative expenses were $17.8 million, compared to $19.4 million in 2023, reflecting an 8.2% decrease.
| Period | General & Administrative Expenses ($ millions) | Percentage Change (%) |
|---|---|---|
| Q3 2024 | 5.0 | -19.1 |
| YTD Q3 2024 | 17.8 | -8.2 |
Alpha Teknova, Inc. (TKNO) - Business Model: Revenue Streams
Sales of diagnostic and therapeutic products
For the nine months ended September 30, 2024, Alpha Teknova, Inc. generated total revenue of $28.5 million, with sales of diagnostic and therapeutic products contributing significantly to this figure. Specifically, revenue from Lab Essentials was reported at $22.1 million, while Clinical Solutions revenue was $5.2 million.
| Period | Lab Essentials Revenue (in thousands) | Clinical Solutions Revenue (in thousands) | Total Revenue (in thousands) |
|---|---|---|---|
| Q3 2024 | $7,161 | $1,964 | $9,576 |
| Q3 2023 | $7,274 | $597 | $8,169 |
| 9M 2024 | $22,065 | $5,247 | $28,480 |
| 9M 2023 | $22,112 | $5,859 | $28,817 |
Revenue from customized product solutions
Alpha Teknova's revenue from customized product solutions is a growing segment. The increase in Clinical Solutions revenue by $1.4 million or 229% for the three months ended September 30, 2024, indicates a rising demand for tailored solutions to meet specific customer needs. The company attributes this growth to an increased number of customers and higher average revenue per customer.
Potential income from partnerships and collaborations
While specific figures for partnerships and collaborations are not detailed, Alpha Teknova's business model is supported by its ISO 13485:2016 certification, allowing it to manufacture products for diagnostic and therapeutic applications. This certification enhances its ability to engage in partnerships and collaborations within the healthcare sector, potentially increasing revenue through joint ventures and research initiatives.
Limited international sales, primarily in U.S. dollars
International sales for the nine months ended September 30, 2024, were $1.3 million, representing 4.7% of total revenue. This figure reflects a slight increase from $1.2 million or 4.1% of total revenue during the same period in 2023. All international sales are conducted in U.S. dollars, which mitigates foreign exchange risks for the company.
| Period | International Revenue (in thousands) | Percentage of Total Revenue |
|---|---|---|
| Q3 2024 | $519 | 5.4% |
| Q3 2023 | $342 | 4.2% |
| 9M 2024 | $1,325 | 4.7% |
| 9M 2023 | $1,189 | 4.1% |
Updated on 16 Nov 2024
Resources:
- Alpha Teknova, Inc. (TKNO) Financial Statements – Access the full quarterly financial statements for Q3 2024 to get an in-depth view of Alpha Teknova, Inc. (TKNO)' financial performance, including balance sheets, income statements, and cash flow statements.
- SEC Filings – View Alpha Teknova, Inc. (TKNO)' latest filings with the U.S. Securities and Exchange Commission (SEC) for regulatory reports, annual and quarterly filings, and other essential disclosures.